Skip to content

Strengthen the long-term management of hyperkalemia in hemodialysis patients based on the pattern of blood potassium changes

Strengthen the long-term management of hyperkalemia in hemodialysis patients based on the pattern of blood potassium changes

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119050
Enrollment
Unknown
Registered
2026-02-14
Start date
2024-09-09
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperkalemia

Interventions

Experimental Group:Blood potassium (5.0-6.0mmol/L), 5g of sodium zirconium cyclosilicate orally administered daily on non-dialysis days
Blood potassium (>6.0mmol/L), 10g of sodium zirconium cyclosilicate orally per day on non-dialysis days
After the blood potassium control target was reached (4.0-5.0mmol/L), 2.5g of SZC was orally administered daily for maintenance on non-dialysis days. If the blood potassium level is less than 4.0mmol/
Control group:Hemodialysis (HD) was performed using dialysate with a potassium ion concentration of 2.0mmol/L three times a week. The Single-Pool urea clearance index (single-pool Kt/V, spKt/V) reache

Sponsors

Lin'an District First People's Hospital of Hangzhou (Affiliated Lin'an People's Hospital of Hangzhou Medical College)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years; 2. Eligible for long-term hemodialysis, dialysis duration of more than 3 months; 3. Meet the diagnostic criteria for hyperkalemia (using pre-dialysis blood samples, with results showing serum potassium >5.0 mmol/L on two occasions, and the last serum potassium >5.0 mmol/L); 4. Randomly include patients who are routinely using RAASi medications (including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers).

Exclusion criteria

Exclusion criteria: 1. Patients with acute renal failure undergoing hemodialysis; 2. Hyperkalemia caused by potassium supplements and other potassium-sparing drugs; 3. Patients with severe primary diseases involving the heart, brain, liver, or hematopoietic system; patients with a history of or newly diagnosed tumors; 4. Patients with a history of mental disorders; 5. Patients who do not agree to participate in this study.

Design outcomes

Primary

MeasureTime frame
Blood potassium;

Secondary

MeasureTime frame
Blood calcium;Blood magnesium;Serum albumin;Hemoglobin;Muscle mass;

Countries

China

Contacts

Public ContactYan Jiang

Lin'an District First People's Hospital of Hangzhou (Affiliated Lin'an People's Hospital of Hangzhou Medical College)

jiangyan@hmc.edu.cn+86 136 8578 2777

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 22, 2026